TrialCancer immunology, immunotherapy : CII2021

Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.

Gilberto Filaci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.